CRISPR/Cas9 engineered T cells showed high efficiency and safety in cancer immunotherapy46–49, we therefore explored the potential usage of SynCRISPR-Cas3 for genome editing in human cells by disrupting T-cell receptor α constant (TRAC) locus in CD3+ T cells. This evidence concerns the gene EFS and cancer.